Loading
A phase 1 trial of Ilixadencel run by Mendus, terminated.
A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer is a phase 1 interventional study registered as NCT03735290 by Mendus, with 21 participants enrolled, started 2019-01-14. Conditions recorded: Carcinoma, Squamous Cell of Head and Neck, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma and Non-small Cell Lung Cancer. Interventions recorded: ilixadencel and Pembrolizumab.
Shares Ilixadencel, Mendus and the tag pipeline.
Shares Ilixadencel, Mendus and the tag pipeline.
Shares Ilixadencel, Mendus and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Mendus and the tag pipeline.
Shares Mendus and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/